Metabolomik: Open Access

Lipid Metabolism Profiling and Bladder Cancer

Abstract

Besiroglu H

Current clinical studies on lipidomics have revealed some outcomes that could have a great effect on treating the possible pathophysiological mechanisms through new molecular targets rather than the phenotyping results of diseases. Bladder cancer is one of the leading cancers in the field of urology and a leading cause of cancer-related death. Beside its very common epidemiology, it is a highly heterogeneous disease. Non-muscle invasive bladder cancer definition includes a fully heterogeneous disease spectrum that involves Ta low grade and T1 high grade diseases, which are completely different for recurrence, progression and disease free survival rates. From this perspective, it is essential to research new target metabolites in an attempt to elucidate the underlying mechanisms to provide a more satisfactory and individualized approach in the diagnosis, treatment and prognosis for patients with bladder cancer. Lipids have many roles in cellular structure and function. They are structural scaffolds and mediators of signal transduction as well as serving as metabolic fuels. The development in lipidomic research are promising to identify new metabolites in this highly complex and heterogeneous cancer type but more studies are warranted to eluciadate the role of complex lipid metabolism in tumor pathophysiology as well as to find out targeted molecules for treatment and prognosis management in clinical settings.